When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 5, 2013, Pages 779-787

  Cheng, Gang ^a,b   Torigian, Drew A ^b   Zhuang, Hongming ^c   Alavi, Abass ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cancer; Diagnosis; Dual time point imaging; FDG; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

BREAST CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSENSUS; DELAYED TIME POINT IMAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISTANT METASTASIS; DUAL TIME POINT IMAGING; EXPERIMENTAL DESIGN; GRANULOMATOUS INFLAMMATION; HUMAN; IMAGING; INFLAMMATION; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; PANCREAS CANCER; PRACTICE GUIDELINE; PREVALENCE; RADIATION FIELD; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARD; TUMOR DIFFERENTIATION; TUMOR VOLUME; DIAGNOSTIC USE; NEOPLASM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; TIME; METHODOLOGY;

FLUORODEOXYGLUCOSE F18; HUMANS; INFLAMMATION; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS;

EID: 84891724026     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2343-9     Document Type: Review

References (93)

1. Cheng G, Alavi A, Zhuang H. Clinical application of FDG PET/CT in pediatric lymphoma patients. PET Clin. 2012;7:47-56.
2. Hustinx R, Smith RJ, Benard F, Rosenthal DI, Machtay M, Farber LA, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345-8.
3. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. JNuclMed. 2001;42:1412-7.
4. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med. 2005;46:1819-24.
5. 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47:1440-6.
6. Xiu Y, Bhutani C, Dhurairaj T, Yu JQ, Dadparvar S, Reddy S, et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med. 2007;32:101-5.
7. Alkhawaldeh K, Bural G, Kumar R, Alavi A. Impact of dual-timepoint (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2008;35:246-52.
8. Schillaci O, Travascio L, Bolacchi F, Calabria F, Bruni C, Ciccio C, et al. Accuracy of early and delayed FDG PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients. Radiol Med. 2009;114:890-906.
9. Lee JW, Kim SK, Lee SM, Moon SH, Kim TS. Detection of hepatic metastases using dual-time-point FDG PET/CTscans in patients with colorectal cancer. Mol Imaging Biol. 2011;13:565-72.
10. Shinya T, Fujii S, Asakura S, Taniguchi T, Yoshio K, Alafate A, et al. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma. Ann Nucl Med. 2012;26:616-21.
11. Gallagher BM, Ansari A, Atkins H, Casella V, Christman DR, Fowler JS, et al. Radiopharmaceuticals XXVII. 18F-labeled 2- deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med. 1977;18:990-6.
12. Chang CC, Cho SF, Chen YW, Tu HP, Lin CY, Chang CS. SUVon dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma. Clin Nucl Med. 2012;37:e189-95.
13. Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, et al. Relationship between retention index in dual-phase (18)FFDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-80.
14. 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5. AJR Am J Roentgenol. 2008;191:475-9.
15. 18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort? Eur J Nucl Med Mol Imaging. 2008;35:1305-15.
16. 18F-FDG-PET imaging for pulmonary lesions. Nucl Med Commun. 2009;30:455-61.
17. Sathekge MM, Maes A, Pottel H, Stoltz A, van de Wiele C. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med J. 2010;100:598-601.
18. Kim DW, Kim CG. Dual-time point positron emission tomography findings of benign mediastinal lymph nodes in a tuberculosisendemic region. Jpn J Radiol. 2011;29:682-7.
19. Umeda Y, Demura Y, Morikawa M, Ameshima S, Tsuchida T, Fujibayashi Y, et al. Prognostic value of dual-time-point 18Ffluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis. Respirology. 2011;16:713-20.
20. 18F-FDG PET-CT in non-small cell lung cancer: additional diagnostic value of CT attenuation and dual-timepoint imaging. Eur J Radiol. 2012;81:1886-90.
21. Zheng Z, Pan Y, Guo F, Wei H, Wu S, Pan T, et al. Multimodality FDG PET/CT appearance of pulmonary tuberculoma mimicking lung cancer and pathologic correlation in a tuberculosis-endemic country. South Med J. 2011;104:440-5.
22. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with 18FFDG PET/CT 1.0. J Nucl Med. 2006;47:885-95.
23. Dirisamer A, Halpern BS, Schima W, Heinisch M, Wolf F, Beheshti M, et al. Dual-time-point FDG-PET/CT for the detection of hepatic metastases. Mol Imaging Biol. 2008;10:335-40.
24. Alkhawaldeh K, Biersack HJ, Henke A, Ezziddin S. Impact of dual-time-point F-18 FDG PET/CT in the assessment of pleural effusion in patients with non-small-cell lung cancer. Clin Nucl Med. 2011;36:423-8.
25. 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients. Acta Radiol. 2012;53:518-23.
26. Ma SY, See LC, Lai CH, Chou HH, Tsai CS, Ng KK, et al. Delayed (18)F-FDG PET for detection of paraaortic lymph nodemetastases in cervical cancer patients. J Nucl Med. 2003;44:1775-83.
27. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44:540-8.
28. 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? Eur J Nucl Med Mol Imaging. 2005;32:541-8.
29. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871-5.
30. Lan XL, Zhang YX,Wu ZJ, Jia Q,Wei H, Gao ZR. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions. Clin Radiol. 2008;63:756-64.
31. Nishiyama Y, Yamamoto Y, Kimura N, Ishikawa S, Sasakawa Y, Ohkawa M. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer. Ann Nucl Med. 2008;22:245-50.
32. Kim SJ, Kim YK, Kim IJ, Kim YD, Lee MK. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients. Clin Nucl Med. 2011;36:434-9.
33. Hu M, Han A, Xing L, Yang W, Fu Z, Huang C, et al. Value of dual-time-point FDG PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity. Clin Nucl Med. 2011;36:429-33.
34. Nakamura S, Okochi K, Kurabayashi T. Dual-time-point fluorodeoxyglucose positron emission tomography for diagnosis of cervical lymph node metastases in patients with head and neck squamous cell carcinoma. J Comput Assist Tomogr. 2011;35:303-7.
35. Cloran FJ, Banks KP, Song WS, Kim Y, Bradley YC. Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer. 2010;68:66-71.
36. Hu Q,WangW, Zhong X, Yuan S, Fu Z, Guo H, et al. Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer. Eur J Radiol. 2009;70:320-4.
37. Kim SJ, Kim YK, Kim IJ, Kim YD, Lee MK. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC). Radiother Oncol. 2011;98:105-8.
38. 18F-FDG-avid non-small cell lung cancer and benign lesions. Ann Nucl Med. 2009;23:427-35.
39. Macdonald K, Searle J, Lyburn I. The role of dual time point FDG PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5. Clin Radiol. 2011;66:244-50.
40. Suga K, Kawakami Y, Hiyama A, Matsunaga N. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18- fluorodeoxy-glucose PET/CTscan. Ann Nucl Med. 2009;23:399-407.
41. Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, et al. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan. Ann Nucl Med. 2009;23:523-31.
42. Sanghera B, Wong WL, Lodge MA, Hain S, Stott D, Lowe J, et al. Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun. 2005;26:861-7.
43. Basu S, Mavi A, Cermik T, Houseni M, Alavi A. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology? Mol Imaging Biol. 2008;10:62-6.
44. Tian R, Su M, Tian Y, Li F, Li L, Kuang A, et al. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions. Skeletal Radiol. 2009;38:451-8.
45. Kim DW, Jung SA, Kim CG, Park SA. The efficacy of dual time point F-18 FDG PET imaging for grading of brain tumors. Clin Nucl Med. 2010;35:400-3.
46. Fuster D, Lafuente S, Setoain X, Navales I, Perissinotti A, Pavia J, et al. Dual-time point images of the liver with (18)F-FDG PET/CT in suspected recurrence from colorectal cancer. Rev Esp Med Nucl. 2012;31:111-6.
47. Kubota K, Yokoyama J, Yamaguchi K, Ono S, Qureshy A, Itoh M, et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur J Nucl Med Mol Imaging. 2004;31:590-5.
48. Fischman AJ, Alpert NM. FDG-PET in oncology: there's more to it than looking at pictures [editorial]. J Nucl Med. 1993;34:6-11.
49. Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med. 1995;36:883-7.
50. Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696-703.
51. 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med. 2006;47:633-8.
52. Arena V, Skanjeti A, Casoni R, Douroukas A, Pelosi E. Dual-phase FDG-PET: delayed acquisition improves hepatic detectability of pathological uptake. Radiol Med. 2008;113:875-86.
53. Cheng G, Alavi A, Lim E, Werner TJ, Del Bello CV, Akers SR. Dynamic changes of FDG uptake and clearance in normal tissues. Mol Imaging Biol. 2012. doi:10.1007/s11307-012-0600-0.
54. Gupta N, Gill H, Graeber G, Bishop H, Hurst J, Stephens T. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions. Chest. 1998;114:1105-11.
55. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Tsutsui K, Wakabayashi H, et al. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun. 2005;26:895-901.
56. Chen YM, Huang G, Sun XG, Liu JJ, Chen T, Shi YP, et al. Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan. Nucl Med Commun. 2008;29:425-30.
57. Shinya T, Rai K, Okumura Y, Fujiwara K, Matsuo K, Yonei T, et al. Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer. Clin Nucl Med. 2009;34:216-21.
58. Beaulieu S, Kinahan P, Tseng J, Dunnwald LK, Schubert EK, Pham P, et al. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med. 2003;44:1044-50.
59. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35:1308-12.
60. Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E. Dual time point FDG-PET/CT imaging Potential tool for diagnosis of breast cancer. Clin Radiol. 2008;63:1213-27.
61. Kikuchi M, Nakamoto Y, Shinohara S, Fujiwara K, Tona Y, Yamazaki H, et al. Suture granuloma showing false-positive finding on PET/CT after head and neck cancer surgery. Auris Nasus Larynx. 2012;39:94-7.
62. Ho L, Wassef H, Seto J. FDG PET/CT imaging in granulomatous changes secondary to breast silicone injection. Clin Radiol. 2010;65:659-61.
63. Prosch H, Mirzaei S, Oschatz E, Strasser G, Huber M, Mostbeck G. Case report: gluteal injection site granulomas: false positive finding on FDG-PET in patients with non-small cell lung cancer. Br J Radiol. 2005;78:758-61.
64. Kirsch CFE, Suh JD, Lufkin RB, Canalis RF. False-positive positron-emission tomography-CT of a Teflon granuloma in the parapharyngeal space occurring after treatment for a patulous eustachian tube. AJNR Am J Neuroradiol. 2007;28:1371-2.
65. Morishita K, Otomo Y, Sasaki H, Yamashiro T, Okubo K. Multiple abdominal granuloma caused by spilled gallstones with imaging findings that mimic malignancy. Am J Surg. 2010;199:e23-4.
66. Lim ST, Jeong H-J, Kim DW, Yim C-Y, Sohn M-H. F-18 FDG PET-CT findings of intraperitoneal carbon particles-induced granulomas mimicking peritoneal carcinomatosis. Clin Nucl Med. 2008;33:321-4.
67. Tenconi S, Luzzi L, Paladini P, Voltolini L, Gallazzi MS, Granato F, et al. Pleural granuloma mimicking malignancy 42 years after slurry talc injection for primary spontaneous pneumothorax. Eur Surg Res. 2010;44:201-3.
68. Miyake KK, Nakamoto Y,Mikami Y, Ishizu K, Saga T, Higashi T, et al. F-18 FDG PETof foreign body granuloma: pathologic correlation with imaging features in 3 cases. Clin Nucl Med. 2010;35:853-7.
69. Cheng G, Torigian DA, Alavi A. FDG PET/CT and MRI findings in a patient with focal xanthogranulomatous pyelonephritis mimicking cystic renal malignancy. Clin Nephrol. 2011;76:484-6.
70. Makino I, Yamaguchi T, Sato N,Yasui T, Kita I. Xanthogranulomatous cholecystitis mimicking gallbladder carcinoma with a false-positive result on fluorodeoxyglucose PET. World J Gastroenterol. 2009;15:3691-3.
71. Li Y-J, Zhang Y, Gao S, Bai R-J. Cervical and axillary lymph node sarcoidosis misdiagnosed as lymphoma on F-18 FDG PET-CT. Clin Nucl Med. 2007;32:262-4.
72. Cheng C-Y, HuangW-S, Shen DH, Fan Y-M, Hsu H-H, Cherng S-C, et al. FDG PET/CT demonstrated rapid progression of mediastinal lymphadenopathy in sarcoidosis. Clin Nucl Med. 2007;32:117-21.
73. Prabhakar HB, Rabinowitz CB, Gibbons FK, O'DonnellWJ, Shepard J-AO, Aquino SL. Imaging features of sarcoidosis on MDCT, FDG PET, and PET/CT. AJR Am J Roentgenol. 2008;190:S1-6.
74. Razak HR, Geso M, Abdul Rahim N, Nordin AJ. Imaging characteristics of extrapulmonary tuberculosis lesions on dual time point imaging (DTPI) of FDG PET/CT. J Med Imaging Radiat Oncol. 2011;55:556-62.
75. Nunez R, Kalapparambath A, Varela J. Improvement in sensitivity with delayed imaging of pulmonary lesions with FDG-PET. Rev Esp Med Nucl. 2007;26:196-207.
76. Basu S, Kwee TC, Gatenby R, Saboury B, Torigian DA, Alavi A. Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J NuclMed Mol Imaging. 2011;38:987-91.
77. Asselin M-C, O'Connor JPB, Boellaard R, Thacker NA, Jackson A. Quantifying heterogeneity in human tumours using MRI and PET. Eur J Cancer. 2012;48:447-55.
78. Beresford M, Sanghera B, Wong W-L, Makris A. Imaging of primary breast cancer with 18F-fluorodeoxythymidine PET-CT reveals heterogeneity of proliferation throughout the tumour. Eur J Nucl Med Mol Imaging. 2006;33:624.
79. Sorensen M, Horsman MR, Cumming P, Munk OL, Keiding S. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode PO2 measurements in murine tumors. Int J Radiat Oncol Biol Phys. 2005;62:854-61.
80. Wyss MT, Hofer S, Hefti M, Bartschi E, Uhlmann C, Treyer V, et al. Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake. J Nucl Med. 2007;48:1047-52.
81. Hatt M, Cheze-le Rest C, van Baardwijk A, Lambin P, Pradier O, Visvikis D. Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med. 2011;52:1690-7.
82. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med. 2004;45:1653-9.
83. 18F-FDG PET images for brain tumor identification and delineation. J Nucl Med. 2011;52:865-72.
84. Horky LL, Hsiao EM, Weiss SE, Drappatz J, Gerbaudo VH. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol. 2011;103:137-46.
85. Chin BB, Green ED, Turkington TG, Hawk TC, Coleman RE. Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol. 2009;11:118-22.
86. Deppen S, Putnam Jr. JB, Andrade G, Speroff T, Nesbitt JC, Lambright ES, et al. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg. 2011;92:428-32.
87. Alavi A, Gupta N, Alberini J-L, Hickeson M, Adam L-E, Bhargava P, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med. 2002;32:293-321.
88. 18F-FDG PET for the diagnosis of thoracic malignancy. Nucl Med Commun. 2003;24:1129-37.
89. 18F-FDG PET for staging in patients with lung cancer. J Nucl Med. 2008;49:1606-12.
90. 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun. 2005;26:315-21.
91. Nishiyama Y, Yamamoto Y, Kimura N, Miki A, Sasakawa Y, Wakabayashi H, et al. Comparison of early and delayed FDG PET for evaluation of biliary stricture. Nucl Med Commun. 2007;28:914-9.
92. Kim SJ, Kim BH, Jeon YK, Kim SS, Kim IJ. Limited diagnostic and predictive values of dual-time-point 18F FDG PET/CT for differentiation of incidentally detected thyroid nodules. Ann Nucl Med. 2011;25:347-53.
93. 18F-FDG PET in characterizing thyroid incidentalomas. Clin Radiol. 2011;66:1197-202.